2023 World Conference on Lung Cancer (Posters)-P2.02. Comprehensive Pneumonitis Assessment Among Inoperable Stage III NSCLC Patients Treated with Chemoradiotherapy-Immunotherapy Regimen

P2.02. Comprehensive Pneumonitis Assessment Among Inoperable Stage III NSCLC Patients Treated with Chemoradiotherapy-Immunotherapy Regimen - PDF(Slides)

Back to course

Pdf Summary

This study examines the rates and severity of pneumonitis in inoperable Stage III Non-Small Cell Lung Cancer (NSCLC) patients treated with a chemoradiotherapy-immunotherapy regimen. The researchers conducted a retrospective review of electronic medical records from 2018 to 2022 and included patients who received either concurrent or sequential chemotherapy-radiotherapy followed by Durvalumab. The rates of pneumonitis were evaluated using CBCT and diagnostic CT scan images.<br /><br />The results showed that the overall rates of clinical pneumonitis were higher in patients receiving Durvalumab immunotherapy compared to those who did not. Additionally, the study found that concurrent chemoradiotherapy (cCRT) and Durvalumab were independent prognostic factors that increased the risk of clinical pneumonitis.<br /><br />The study also compared the progression-free survival (PFS) in patients receiving cCRT or sequential CRT (sCRT) with or without Durvalumab. It was found that adjuvant Durvalumab improved PFS in both cCRT and sCRT groups. The findings were consistent with the results of the Pacific trial.<br /><br />The researchers concluded that Durvalumab and cCRT are associated with an increased risk of clinical pneumonitis. However, dosimetric parameters such as tumor volume and radiation doses were not found to be associated with the risk of developing pneumonitis.<br /><br />This study provides valuable insights into the interplay of adverse events from radiotherapy, chemotherapy, and Durvalumab in the treatment of inoperable Stage III NSCLC. It highlights the importance of monitoring and managing pneumonitis in patients undergoing this treatment regimen. Further analysis on rates of pseudoprogression and hyperprogression using the same patient population is ongoing.

Asset Subtitle

Jayson Paragas

Meta Tag

Speaker Jayson Paragas

Topic Local-Regional NSCLC: Toxicities of Multimodality Therapy

Keywords

pneumonitis

inoperable Stage III Non-Small Cell Lung Cancer

chemoradiotherapy-immunotherapy regimen

retrospective review

electronic medical records

Durvalumab

concurrent chemoradiotherapy

sequential chemoradiotherapy

progression-free survival

adverse events